VBI Vaccines Inc. (VBIV)

VBI Vaccines Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	12.6	23.69	62.63	121.69	93.83	44.21
Short-Term Investments	0	0	0	0	25.28	0
Cash & Cash Equivalents	12.6	23.69	62.63	121.69	119.1	44.21
Cash Growth	-68.82%	-62.18%	-48.54%	2.18%	169.38%	-25.40%
Receivables	0.23	0	0.09	0.01	0.08	0.2
Inventory	9.94	8.5	6.6	2.58	2.15	1.08
Other Current Assets	3.6	4.05	8.37	6.01	10.71	1.47
Total Current Assets	26.36	36.23	77.69	130.28	132.04	46.96
Property, Plant & Equipment	11.04	11.91	15.57	14.38	12.28	11.65
Goodwill and Intangibles	36.84	37.63	60.47	64.35	64.42	62.96
Other Long-Term Assets	1.21	1.18	1.36	1.26	0.64	0.62
Total Long-Term Assets	49.08	50.72	77.4	79.99	77.33	75.24
Total Assets	75.44	86.95	155.09	210.28	209.37	122.2
Accounts Payable	8.87	6.43	12.97	4.28	3.73	1.13
Deferred Revenue	11.23	9.11	2.61	2.8	3.1	3.79
Current Debt	49.58	51.75	0.97	0.84	0.94	15.49
Other Current Liabilities	7.92	8.45	20.38	24.66	9.57	9.35
Total Current Liabilities	77.59	75.74	36.94	32.59	17.35	29.76
Long-Term Debt	1.14	1.3	51.25	30.96	16.95	0.82
Other Long-Term Liabilities	2.18	2.39	2.73	2.85	3.37	3.37
Total Long-Term Liabilities	3.32	3.69	53.98	33.81	20.32	4.19
Total Liabilities	80.91	79.42	90.92	66.39	37.67	33.95
Total Debt	50.71	53.04	52.23	31.8	17.89	16.3
Debt Growth	-3.17%	1.56%	64.25%	77.71%	9.74%	16.23%
Retained Earnings	-600.35	-582.45	-489.61	-378.37	-308.62	-262.39
Comprehensive Income	31.81	28.33	21.44	-1.57	1.27	-0.75
Shareholders' Equity	-5.47	7.53	64.16	143.88	171.71	88.26
Net Cash / Debt	-38.12	-29.36	10.4	89.9	101.21	27.91
Net Cash / Debt Growth	-	-	-88.43%	-11.18%	262.64%	-38.31%
Net Cash Per Share	-1.55	-1.89	1.21	10.58	13.91	7.01
Working Capital	-51.23	-39.51	40.75	97.7	114.69	17.21
Book Value Per Share	-0.22	0.48	7.45	16.93	23.60	22.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).